Translational Research in Maternal and Pediatric Pharmacology and Therapeutics
UpcomingNational Institutes of Health · Opportunity number PAR-28-059 · Forecast
Eligibility
Nonprofits are listed as eligible applicants.
- For profit organizations other than small businesses
- Small businesses
- Public and state controlled institutions of higher education
- County governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- City or township governments
- Independent school districts
- Native American tribal governments (Federally recognized)
- Special district governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Private institutions of higher education
- Public housing authorities/Indian housing authorities
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), intends to renew and publish a Notice of Funding Opportunity (NOFO) to solicit applications to promote translational and clinical research in pregnant women, lactating women, infants, children, and adolescents to: (1) advance precision medicine through the development, testing, and implementation of novel tools, models, and other technologies; (2) discover and develop novel therapeutics or enhance the usage of existing drugs for safer and more effective medications; (3) enhance patient-provider communications about drug effectiveness and safety risks; and, (4) optimize the dissemination, implementation, sustainment, and scale-up of evidence-based interventions to these patient populations. The overall goal is to improve safe and effective precision therapeutics during pregnancy, lactation, and across childhood. Applications are not being solicited at this time.
Funding
| Total program funding | Not listed |
|---|---|
| Award floor | Not listed |
| Award ceiling | Not listed |
| Category | Health |
| Assistance listing | 93.865 |
Official sources
Last verified on Grants.gov Nov 4, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.